# Ruijin Hospital: Phase 2 study in Poor Graft Function, Myelodysplastic Syndromes (66 participants)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Ruijin Hospital |
| Sponsor type | Academic and hospital |
| Study | Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT |
| NCT ID | NCT07888348 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Poor Graft Function; Myelodysplastic Syndromes; Hematopoietic Stem Cell Transplantation |
| Intervention types | biological |
| Target enrollment | 66 |
| Site countries | China |
| Posted | 2026-10-22 |
| Planned start | 2026-10-05 |
| Event | Newly registered study |
| Event date | 2026-10-22 |

## Why this score
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07888348). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.